Search

everythinglearnresearchcommunity

for

Search:↓

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

The conversation is about a user struggling with hair loss despite using dutasteride, finasteride, minoxidil, and dermaneedling. The user is considering other treatments but is hesitant to use RU-58841 due to side effects and is seeking advice on alternative solutions.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Minoxidil and finasteride have stabilized hair loss but not significantly improved regrowth. The user is considering dutasteride, oral Minoxidil, or a hair transplant for better results.

The user halted hair loss using 0.01% topical liposomal finasteride daily, with no side effects or regrowth, and recently added 5% minoxidil and low-level laser therapy. They recommend this conservative approach for those hesitant about finasteride.

Bicalutamide is discussed as a treatment for hair loss, particularly in females, with some users cautioning against its use due to potential side effects. The conversation also mentions using finasteride and other anti-androgens, with some users recommending more traditional treatments like dutasteride.

A user is considering a serum with Redensyl, Anagain, and Procapil for male pattern baldness. They are asking if it will be effective.

A user is considering tapering off finasteride due to concerns about long-term side effects and cost, and is exploring alternatives like zinc and saw palmetto. Their current regimen includes finasteride, Adderall, zinc, bupropion, fish oil, baby aspirin, Rogaine foam, and ketoconazole shampoo.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

The user has been using finasteride, minoxidil, and nizoral for hair loss but hasn't seen regrowth, only maintenance. They are considering switching to dutasteride, which is believed to be more effective, but are concerned about potential side effects.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

The conversation discusses hair loss treatments, specifically asking about clinics in the US that perform dutasteride mesotherapy. Minoxidil, finasteride, and RU58841 are also mentioned.

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

New hair loss treatments include topical and gel formulations combining finasteride and dutasteride, with added caffeine and melatonin. The user reports positive results from using topical dutasteride.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

The conversation discusses managing estradiol problems during finasteride treatment. Suggestions include stopping finasteride every 3 months for 2-3 weeks or reducing the dosage.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

Treatment options for hair regrowth other than minoxidil or finasteride, due to side effects from the latter, with platelet-rich plasma and topical treatments being among the suggested alternatives.

OP seeks advice on alternative hair loss treatments like Redensyl, Capixyl, and Procapil, instead of lifelong Minoxidil and Finasteride. Users suggest hair transplants and discuss the potential future availability of better treatments.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

There is no reliable ranking for the effectiveness of topical anti-androgens like Fluridil, RU58841, and Pyrilutamide, with limited studies available. Some users suggest Pyrilutamide may be promising based on ongoing trials, while Fluridil combined with finasteride has shown positive results for some individuals.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.